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Abstract
Bronchodilators are a standard medicine for treating airway obstructive diseases, and b2 adrenergic receptor agonists have
been the most commonly used bronchodilators since their discovery. Strikingly, activation of G-protein-coupled bitter taste
receptors (TAS2Rs) in airway smooth muscle (ASM) causes a stronger bronchodilation in vitro and in vivo than b2 agonists,
implying that new and better bronchodilators could be developed. A critical step towards realizing this potential is to
understand the mechanisms underlying this bronchodilation, which remain ill-defined. An influential hypothesis argues that
bitter tastants generate localized Ca2+ signals, as revealed in cultured ASM cells, to activate large-conductance Ca2+-
activated K+ channels, which in turn hyperpolarize the membrane, leading to relaxation. Here we report that in mouse
primary ASM cells bitter tastants neither evoke localized Ca2+ events nor alter spontaneous local Ca2+ transients.
Interestingly, they increase global intracellular [Ca2+]i, although to a much lower level than bronchoconstrictors. We show
that these Ca2+ changes in cells at rest are mediated via activation of the canonical bitter taste signaling cascade (i.e., TAS2R-
gustducin-phospholipase Cb [PLCb]- inositol 1,4,5-triphosphate receptor [IP3R]), and are not sufficient to impact airway
contractility. But activation of TAS2Rs fully reverses the increase in [Ca2+]i induced by bronchoconstrictors, and this lowering
of the [Ca2+]i is necessary for bitter tastant-induced ASM cell relaxation. We further show that bitter tastants inhibit L-type
voltage-dependent Ca2+ channels (VDCCs), resulting in reversal in [Ca2+]i, and this inhibition can be prevented by pertussis
toxin and G-protein bc subunit inhibitors, but not by the blockers of PLCb and IP3R. Together, we suggest that TAS2R
stimulation activates two opposing Ca2+ signaling pathways via Gbc to increase [Ca2+]i at rest while blocking activated L-
type VDCCs to induce bronchodilation of contracted ASM. We propose that the large decrease in [Ca2+]i caused by effective
tastant bronchodilators provides an efficient cell-based screening method for identifying potent dilators from among the
many thousands of available bitter tastants.
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Introduction
Airway obstructive diseases (asthma and chronic obstructive
pulmonary disease [COPD]) have become increasingly prevalent,
currently affecting more than 300 million people worldwide.
Dysfunction of airway smooth muscle (ASM) cells, a major cell
type in the respiratory tree, plays a pivotal role in promoting
progression of these diseases and in contributing to their symptoms
of these diseases [1–3]. With their ability to contract and relax,
these cells regulate the diameter and length of conducting airways,
controlling dead space and resistance to airflow to and from gas-
exchanging areas. Their excessive contraction, as seen in patients
with asthma and COPD, can fully close the airways, thereby
preventing gas exchange and threatening life. Not surprisingly,
bronchodilators have been used as the medication of choice for
asthmatic attacks and as a standard medicine for managing COPD
[4,5]. However, available bronchodilators have adverse side
effects, and are not sufficiently effective for severe asthmatics
and many other COPD patients. A better understanding of the
mechanisms regulating ASM thus holds the promise of developing
more effective and safe bronchodilators, which in turn would have
a significant impact in reducing mortality and morbidity caused by
asthma and COPD.
Bitter tastants represent a new class of compounds with
potential as potent bronchodilators. Deshpande et al. recently
found that cultured ASM cells express G-protein-coupled bitter
taste receptors (TAS2Rs) [6], a class of proteins long thought to be
expressed only in the specialized epithelial cells in the taste buds of
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the tongue that allow organisms to avoid harmful toxins and
noxious substances characterized by bitterness [7–10]. Important-
ly, bitter tastants with diverse chemical structures cause greater
ASM relaxation in vitro than b2 adrenergic agonists, the most
commonly used bronchodilators to treat asthma and COPD
[6,11]. Moreover, these compounds can effectively relieve in vivo
asthmatic airway obstruction than b2 adrenergic agonists in a
mouse model of asthma [6], making them highly attractive
bronchodilators for asthma and COPD.
Bitter tastant-induced bronchodilation was unexpected, because
these agents appeared to increase intracellular Ca2+ concentration
([Ca2+]i) to a level comparable to that produced by potent
bronchoconstrictors [6], which should have led to smooth muscle
contraction [12]. To reconcile this apparent paradox, it was
proposed that bitter tastants activate the canonical bitter taste
signaling pathway (i.e., TAS2R-gustducin-phospholipase Cb
[PLCb]- inositol 1,4,5-triphosphate receptor [IP3R]) to increase
focal Ca2+ release from endoplasmic reticulum, which then
activate large-conductance Ca2+-activated K+ channels thereby
hyperpolarizing the membrane [6]. However, we subsequently
demonstrated through patch-clamp recordings that bitter tastants
do not activate large-conductance Ca2+-activated K+ channels but
rather inhibit them [11]. Moreover, three different large-conduc-
tance Ca2+-activated K+ channel blockers did not affect the
bronchodilation induced by bitter tastants [11]. Therefore, a
different mechanism must be responsible for the bitter tastant-
induced bronchodilation.
The apparent conundrum of putative [Ca2+]i elevation leading
to relaxation may be attributed to the fact that Ca2+ responses to
bitter tastants were assessed in cultured human ASM cells, while
the contractile responses to them were investigated in freshly
dissected ASM tissues [6]. It is well known that cultured smooth
muscle cell lines alter their phenotype (i.e., losing their ability to
contract and relax [13,14]) and it is likely their Ca2+ response is
also modified. Therefore, to understand bitter tastant-induced
bronchodilation, it is necessary to study the contraction and the
underlying signaling in freshly isolated ASM tissues and cells.
Using this approach in the present study, we found that bitter
tastants activate the canonical bitter taste signaling cascade,
slightly increasing global [Ca2+]i in resting cells, but not to a level
sufficient to cause contraction. However, bitter tastants reverse the
increase in [Ca2+]i evoked by bronchoconstrictors, leading to
bronchodilation. This reversal is mediated by the suppression of L-
type voltage-dependent Ca2+ channels (VDCCs) in a gustducin bc
subunit-dependent, yet PLCb- and IP3R-independent manner.
Hence, we propose that TAS2R activation in ASM stimulates two
opposing Ca2+ signaling pathways, both mediated by Gbc
subunits, which increases [Ca2+]i at rest but blocks activated L-
type VDCCs reversing the contraction they cause. These results
provide the cellular and molecular basis of bitter tastant-induced
bronchodilation that occurs in vitro and in vivo. They further
reveal a Ca2+ signal that is well suited for screening and identifying
potent bronchodilators from among the many thousands of
available bitter tastants.
Results
To uncover the mechanism underlying bitter tastant-induced
bronchodilation as demonstrated in both in vitro and in vivo
normal and asthmatic models of mice, and in vitro human airways
([6,11,15,16], we examined how bitter tastants affected both
[Ca2+]i and ASM contraction in freshly isolated airway cells and
tissues from mouse and human. Fluo-3 was used to assess the effect
of bitter tastants on [Ca2+]i; chloroquine and denatonium, two
substances commonly used to study bitter taste signaling, were
used as bitter tastants.
Bitter Tastants Modestly Raise Global [Ca2+]i with No
Change in Force Generation in Native ASM at Rest
We started our analysis by examining the Ca2+ response to
bitter tastants in resting cells. In contrast to the marked increase in
global [Ca2+]i reported in resting cultured human ASM cells [6],
we observed, in resting native ASM cells from mouse, that
chloroquine (0.1 mM–1 mM) only modestly raised global [Ca2+]i
(and to a level much lower than when cells contracted after
application of Mch at 0.1 mM–100 mM) (Figure 1A and Figure
S1A). Chloroquine (330 mM) increased fluo-3 fluorescence (DF/
F0) (i.e., [Ca
2+]i) both in the presence of extracellular Ca
2+
(37.7%68%, n=19) and in its absence (29.3%66%, n=15;
p.0.05), indicating that the source for this chloroquine response is
from internal Ca2+ stores.
To examine whether this modest increase in [Ca2+]i is sufficient
to trigger contraction, we measured smooth muscle force
formation in mouse airways. As shown in (Figure 1B and S1B),
chloroquine (10 mM–1 mM) did not cause contraction of mouse
airways, although there was a tendency to decrease the basal tone
of airways. As a comparison, Mch at concentrations between
0.3 mM and 10 mM induced contraction markedly and in a dose-
dependent manner (Figure 1B and S1B).
Bitter Tastants Do Not Generate Localized Ca2+ Events
Mouse ASM cells exhibit spontaneous Ca2+ sparks resulting
from the opening of ryanodine receptors in the sarcoplasmic
reticulum [17]. To test whether bitter tastants generate local Ca2+
events as proposed by Deshpande et al. [6], we stimulated ASM
cells with chloroquine (10 mM, a concentration around EC50) for
2 min and measured Ca2+ sparks. Off 40 chloroquine-stimulated
cells, 27 cells generated a global [Ca2+]i increase that precluded an
accurate estimate of Ca2+ sparks. In the remaining 13 cells without
a detectable global rise in [Ca2+]i, chloroquine inhibited the spark
frequency but had no effect on the amplitude (frequency [Hz]:
2.1360.24 in control and 1.6260.21 with chloroquine [n=13,
Author Summary
Bitter taste receptors (TAS2Rs), a G-protein-coupled
receptor family long thought to be solely expressed in
taste buds on the tongue, have recently been detected in
airways. Bitter substances can activate TAS2Rs in airway
smooth muscle to cause greater bronchodilation than b2
adrenergic receptor agonists, the most commonly used
bronchodilators. However, the mechanisms underlying this
bronchodilation remain elusive. Here we show that, in
resting primary airway smooth muscle cells, bitter tastants
activate a TAS2R-dependent signaling pathway that results
in an increase in intracellular calcium levels, albeit to a level
much lower than that produced by bronchoconstrictors. In
bronchoconstricted cells, however, bitter tastants reverse
the bronchoconstrictor-induced increase in calcium levels,
which leads to the relaxation of smooth muscle cells. We
find that this reversal is due to inhibition of L-type calcium
channels. Our results suggest that under normal condi-
tions, bitter tastants can activate TAS2Rs to modestly
increase calcium levels, but that when smooth muscle cells
are constricted, they can block L-type calcium channels to
induce bronchodilation. We postulate that this novel
mechanism could operate in other extraoral cells express-
ing TAS2Rs.
bc-Gustducin Inhibits L-Type Ca2+ Channel
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p,0.05, paired Student’s t-test]; amplitude [DF/F0 at the brightest
location]: 20.661.69 in control and 18.161.3 with chloroquine
[n=13, p.0.05, paired Student’s t-test]). To test whether
spontaneous Ca2+ sparks mask the effect of bitter tastants on
other forms of local Ca2+ releases, such as Ca2+ puffs due to the
opening of IP3Rs [18], we examined the Ca2+ responses to
chloroquine in ASM cells pretreated with 100 mM ryanodine. In
these cells, prior to chloroquine application, no spontaneous sparks
were observed (n=14). Chloroquine (10 mM) increased global
[Ca2+] by 12%64% (DF/F0 at its brightest location) in nine cells,
and failed to cause any detectable Ca2+ increase in five cells. There
were no detectable local Ca2+ events produced in any of the 14
cells. These results indicate that chloroquine at 10 mM does not
increase local Ca2+ events (either Ca2+ puffs or Ca2+ sparks).
Bitter Tastants Activate the TAS2R Signaling Pathway to
Modestly Raise Global [Ca2+]i in Native ASM at Rest
We next examined the cause of the modest global [Ca2+]i rise by
bitter tastants. Since in taste cells, bitter tastants bind to TAS2R to
activate the pertussis toxin (PTX) sensitive G-protein gustducin,
which in turn induces a PLCb2 and IP3 signaling cascade [19,20],
we studied whether bitter tastants activate this TAS2R signaling
pathway. In native ASM cells, PTX (1 mg/ml, and 6–8 h
pretreatment), reduced the chloroquine-induced increase in global
Figure 1. Bitter tastants modestly increase intracellular Ca2+ concentration ([Ca2+]i) by activating a canonical TAS2R signaling
cascade. (A) Chloroquine (Chloro) raised [Ca2+]i to a level much less than Mch. [Ca
2+]i was measured with fluo-3 in the form of acetoxymethyl ester,
loaded into isolated mouse ASM cells, and expressed as DF/F0 (%). (B) 1 mM chloro did not contract airways (using tension as its proxy) while 100 mM
Mch caused a robust contraction. Data are mean 6 SEM (n=6 for chloro, and n=5 for Mch). (C) PTX, gallein, anti-bc (MPS-phosducin-like protein C
terminus, a Gbc blocking peptide), U73122, and 2-APB inhibited chloro-induced increase in [Ca2+]i (n= 19–24 cells). Isolated mouse ASM cells were
either pretreated with 1 mg/ml PTX for 6–8 h or with 1 mM anti-bc for 1–2 h or with each of the other compounds listed for 5–10 min. The effects of
PTX and anti-bc were calculated by normalizing the response of chloro to that from the time matched cells without the pretreatments, and the
effects of other three compounds were analyzed by normalizing the response of chloro to its own control without the compound. (D) RT-PCR
transcripts after amplification with primers to TAS2R107, a-gustducin, Gb3, Gc13, PLCb2, and b-actin. Note that no transcript was detected with
TAS2R108 primers. RNAs were isolated from mouse tracheas and mainstem bronchi, and reactions without complementary DNA were used as a
negative control. (E) Cellular distribution of TAS2R107 in three focus planes (bottom, middle, and top) of an isolated mouse ASM cell. The TAS2R107
immunostaining intensity after 3D deconvolution (see Methods) was pseudocolored with the color map on the right. This makes positive (but dim)
pixels more easily distinguished from background. Eight cells showed a similar subcellular distribution pattern.
doi:10.1371/journal.pbio.1001501.g001
bc-Gustducin Inhibits L-Type Ca2+ Channel
PLOS Biology | www.plosbiology.org 3 March 2013 | Volume 11 | Issue 3 | e1001501
[Ca2+]i to 21.1%68.6% of the control cells (n=20; Figure 1C).
Also both gallein (20 mM and 30 min pretreatment), a blocker of
the Gbc dimer of PTX sensitive G proteins, and MPS-phosducin-
like protein C terminus, a Gbc blocking peptide (anti-bc; 1 mM,
and 1 h pretreatment) [21,22] reduced the bitter tastant-mediated
increase in [Ca2+]i to 19.9%68.5% (n=19; Figure 1C) and
18.4%64.8% of the controls, respectively. Finally, U73122
(3 mM), a blocker of PLCb, and 2-aminoethoxydiphenyl borate
(2-APB) (50 mM), an IP3R antagonist, suppressed the bitter
tastant-induced increases in [Ca2+]i to 18.0%65.5% (n=24) and
210.5%67.3% of controls, respectively (Figure 1C). These results
indicate that bitter tastants do activate the TAS2R signaling
transduction pathway (i.e., TAS2R-PTX-sensitive G protein-
PLCb-IP3R) to release Ca2+ from internal stores. This conclusion
is further supported by the finding that mouse ASM cells express
transcripts for TAS2R107, a-gustducin, Gb3, Gc13, and PLCb2
(Figure 1D), and display peripheral localization of TAS2R107
(Figure 1E).
Bitter Tastant-Induced Bronchodilation Is Due to Reversal
of the Rise in Global [Ca2+]i Caused by
Bronchoconstrictors
Bitter tastants at mM levels can modestly increase [Ca2+]i in
resting cells, but this raises a conundrum as they also can fully
relax airways precontracted by bronchoconstrictors [6,11]. In light
of the fact that an increase in [Ca2+]i is the primary signal for
contraction in all smooth muscle, we explored how bitter tastants
affect [Ca2+]i evoked by bronchoconstrictors. To better quantify
these effects, we measured ASM Ca2+ response and cell shortening
at the same time. The cells were stimulated with methacholine
(Mch), a stable analogue of acetylcholine, which is the major
neurotransmitter in parasympathetic nerves. As expected, Mch
(100 mM) rapidly increased [Ca2+]i as fluo-3 fluorescence in-
creased by 162%626% (DF/F0), and concurrently caused cell
shortening by 49%68% (n=21; Figure 2A and 2B). Strikingly,
chloroquine (1 mM) almost completely reversed this [Ca2+]i
increase (i.e., bringing [Ca2+]i down to a level only 15%62%
higher than pre-stimulation levels, n=12, p,0.01 Mch versus
Mch+chloroquine). The reversal of the increase in [Ca2+]i was
closely associated with relaxation in ASM cells from both mouse
(back to 89%67% of the pre-stimulation length; Figure 2B and
Video S1) and human (back to 94%65% of the control length;
Figure S2A). Denatonium (1 mM) generated similar effects on
[Ca2+]i and cell shortening in response to Mch in mouse ASM cells
(n=9).
The inverse relationship between changes in [Ca2+]I and the
resulting cell length (i.e., lowering [Ca2+]i results in cell lengthen-
ing) in response to bitter tastants suggests that bitter tastants reduce
[Ca2+]i, leading to bronchodilation. If this is the case, one would
expect that bitter tastant-induced bronchodilation could be
prevented if [Ca2+]i was clamped to a physiologically high level.
To test this possibility, we used staphylococcal a-toxin
(16,000 units/ml) to make the ASM membrane permeable to
ions such that the intracellular [Ca2+]i could be controlled at will.
A major advantage of using this toxin is that it does not damage
the cells; thus signaling processes such as the G-protein-coupled
receptor mediated signaling remain intact [23]. As shown in
Figure 3A, raising [Ca2+]i to 3 mM caused a robust increase in
tension in mouse airway. More importantly, at this fixed [Ca2+]i
level, denatonium, chloroquine and quinine (all at 1 mM) failed to
relax ASM in the time frame they would have in Mch contracted
airways without a-toxin treatment. Therefore, clamping [Ca2+]i at
mM levels can prevent bitter tastant-induced bronchodilation,
strongly arguing that reduction of [Ca2+]i by bitter tastants is
necessary for their relaxation action. These results further imply
that a decrease in Ca2+ sensitivity is probably not a major
mechanism underlying bitter tastant-induced bronchodilation.
The Prominent Role of L-type Ca2+ Channels in Mediating
Mch-Induced Contraction
Having established that the suppression of [Ca2+]i is necessary
for bitter tastant-induced bronchodilation, we next addressed the
molecule(s) that bitter tastants act on to reduce [Ca2+]i. Before
addressing this critical question, it is appropriate to determine the
Ca2+ pathways underlying Mch-induced contraction because a
controversy persists [24]. Mch activates both the M3 muscarinic
acetylcholine receptor (M3R)-Gq-PLCb-IP3 pathway and the M2
muscarinic acetylcholine receptor (M2R)-Gi/o pathway to raise
Figure 2. Bitter tastants reverse Mch-induced increase in [Ca2+]i
and cell shortening in mouse ASM. (A) Time course of the effect of
chloro (1 mM) on a 100 mM Mch-induced increase in [Ca2+]i (represent-
ed as DF/F0 integrated over the entire cell) and cell shortening. Images
show the changes in [Ca2+]i displayed as fluorescence intensity (rather
than DF/F0 to aid visualization). Cell length is indicated by the red lines.
Images were taken at the time indicated on the time course of [Ca2+]i
(upper panel). (B) Relationships between [Ca2+]i (left axis, blue bars) and
cell length (right axis, red bars) in response to Mch and Chloro. The
letters correspond to the time shown in the upper panel in (A) (n= 23
cells, mean 6 SEM; *p,0.05, **p,0.01 using two-tailed Student’s t-
test). DF/F0 is zero by definition at a, so no blue bar is present at a.
doi:10.1371/journal.pbio.1001501.g002
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[Ca2+]i by releasing Ca
2+ from internal stores and inducing Ca2+
influx from the extracellular space respectively [25,26]. It has also
been suggested that Ca2+ release from the internal stores
contributes to the early phase of Mch-induced contraction, and
Ca2+ influx is required to sustain elevated [Ca2+]i and contraction.
Indeed, we found that the sustained contraction by Mch in mouse
ASM is largely dependent on Ca2+ influx (Figure S3). However,
the route of Ca2+ influx upon muscarinic receptor activation
among different species is highly debatable [24]. Many studies
suggest that L-type Ca2+ channels are the major path of the Ca2+
influx for contraction [27–32]. To determine the role of this
channel in mediating Mch-induced contraction in mouse airways,
we examined whether L-type channel specific blockers inhibit
Mch-induced contraction and the rise in [Ca2+]i. Previous studies
showed that diltiazem, a well-known L-type Ca2+ channel blocker
that belongs to the benzothiazepine class, dose-dependently
reverses Mch-induced contraction when administrated after Mch’s
response reaches a plateau [31–33]. We therefore examined
whether this blocker produces similar inhibition of Mch-induced
airway force generation in mouse and human airways. Figures
S2B and S4A show that diltiazem dose-dependently inhibited
Mch-induced contraction of airways from both species, and,
Figure 3. Suppression of [Ca2+]i by inhibiting L-type VDCCs is necessary for bitter tastant-induced bronchodilation of Mch
precontracted mouse airways. (A) Clamping [Ca2+]i prevented bitter tastants from causing bronchodilation. Mouse airway rings were
permeabilized with a-toxin (see Method), and extracellular [Ca2+]i was set at 1 nM and then switched to 3 mM as indicated under the trace. Seven
individual experiments (two for denatonium, two quinine, and three chloro all at 1 mM) show responses similar to that shown on the left, so the
results were pooled and displayed on the right. Each ring’s normalized tension is its tension at the experiment’s end divided by its tension just prior
to application of bitter tastants, times 100. (B) FPL 64176 (FPL), an L-type VDCC agonist, prevented chloro from reversing the [Ca2+]i rise induced by
100 mM Mch. Left panel: a typical time course; DF/F0 for each curve is scaled to have a value of 100 at the peak before chloro is added. Right panel:
average results of 16 cells. The values are represented as (DF/F0 at the peak after Mch2DF/F0 at 30 s after chloro)/(DF/F0 at the peak after Mch2DF/F0
at basal)6100 (i.e., the decrease due to chloro divided by the increase due to Mch). **p,0.01, control versus +FPL. (C) FPL dose-dependently reversed
chloro-induced bronchodilation (using tension as a proxy measure) in Mch precontracted airways (n=5–7 independent experiments). Data on the
right panels are mean 6 SEM. % relaxation = tension decrease due to chloro divided by tension increase due to Mch,6100. The tension decrease at
each concentration of chloro is measured once the tension stabilizes. The tension decrease at each increased concentration is always measured
relative to the peak tension (i.e., it is total decrease, not the incremental decrease due to the additional chloro which was added).
doi:10.1371/journal.pbio.1001501.g003
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moreover, it reversed the Mch-induced increase in [Ca2+]i by
90.2%62.9% in single isolated mouse ASM cells (n=12 cells). To
further examine whether diltiazem inhibits muscarinic receptor-
mediated contraction, we treated the airways with diltiazem at
different concentrations before Mch administration. Since a
unique feature of diltiazem in inhibiting L-type Ca2+ channels is
its use-dependence of action (i.e., it more likely binds to, and
therefore blocks, channels as they open), in this series of
experiments we challenged the airways twice with KCl to activate
the Ca2+ channels. As shown in Figure S4B, under this condition,
diltiazem dose-dependently suppressed Mch-induced contraction
and at 100 mM it inhibited the force by 85%66% (n=5). To
directly demonstrate that diltiazem inhibits L-type Ca2+ channels,
we studied the effect of diltiazem on L-type Ca2+ currents with
patch-clamp recording. We found that diltiazem dose-dependently
reduced depolarization-induced L-type Ca2+ currents at concen-
trations over the same range as that which blocked contraction
(Figure S4C).
Dihydropyridines (e.g., nisoldipine, nifedipine, and isradipine)
are another well-known class of L-type Ca2+ channel blockers [34–
36]. Previously we found that dihydropyridines can inhibit L-type
Ca2+ current in mouse ASM [17]. To further establish the role of
this class of Ca2+ channels in mediating Mch-induced contraction,
we assessed the effect of nisoldipine on the contraction evoked by
Mch. It is known that dihydropyridines bind stronger to
inactivated Ca2+ channels, thus displaying a so-called voltage
dependent inhibition [37]. Therefore, in this series of experiments,
to facilitate the interaction between nisoldipine and L-type Ca2+
channels, we examined the effect of nisoldipline on Mch-induced
contraction in the presence of 20 mM KCl to modestly depolarize
the membrane. Under this condition, 1 mM nisoldipine inhibited
Mch-induced contraction by 74%68% (n=5; Figure S4D). This
result is similar to the inhibition of this blocker on carbachol-
induced contraction in rat ASM, when it is similarly depolarized
[29]. Hence, with specific L-type Ca2+ channel blockers of distinct
structures we have established that L-type VDCCs are the major
contributor to Ca2+ influx and sustained contraction in response to
Mch in mouse airways.
Bitter Tastants Inhibit L-Type VDCCs to Decrease [Ca2+]i
Evoked by Bronchoconstrictors
Given the prominent role of L-type VDCCs in Mch-induced
sustained contraction in mouse airways, and our and others’
findings that bitter tastants reverse Mch-induced sustained
contractile [6,11], we hypothesized that bitter tastants inhibit L-
type VDCCs, leading to relaxation of airways precontracted by
Mch. To test this possibility, we investigated whether the L-type
VDCC agonist FPL 64176 [38,39] can prevent the inhibitory
effect of bitter tastants on the Mch-induced [Ca2+]i rise and
contraction. At the single cell level, 10 mM FPL prevented
chloroquine from reducing the [Ca2+]i increase caused by Mch
(Figure 3B). At the tissue level, FPL prevented chloroquine from
relaxing Mch precontracted mouse ASM in a dose-dependent
manner (Figure 3C). These results suggest that bitter tastants
inhibit L-type VDCCs, which in turn leads to a decrease in [Ca2+]i
and resulting bronchodilation.
Bitter Tastants Reverse the [Ca2+]i Rise and Contraction
Evoked by Depolarization-Induced Activation of L-Type
VDCCs
To directly examine the inhibitory role of bitter tastants on L-
type VDCCs, we studied the effect of bitter tastants on L-type
VDCC currents using patch clamp recording. Figure 4A shows
two representative traces of L-type Ca2+ currents evoked by a
depolarizing pulse to 0 mV from a holding potential of 270 mV
(left panel) and mean peak currents at different depolarizing
voltages (right panel) before and after 1 mM chloroquine. As is
evident, chloroquine inhibited the L-type Ca2+ current when
depolarizing voltages are between 230 mV and +40 mV.
To study whether this inhibition by chloroquine of L-type
VDCCs could produce relaxation, we evaluated the effect of this
bitter tastant on the depolarization-induced increase in [Ca2+]i
and contraction. KCl is a standard and common reagent used to
study cellular processes mediated by depolarization. In airways,
depolarization is expected to not only activate VDCCs in ASM
but also those in cholinergic nerves as well (leading to release of
Ach). Indeed, in ferret and pig, KCl activates both mechanisms to
cause airway contraction [40,41]. However, the Ach release
mechanism does not operate in dog and rabbit airway, as
demonstrated by several reports that showed that atropine, a
muscarinic receptor antagonist, had no measureable effect on the
magnitude of tension generated by high K+ in these species [42–
44]. Therefore to determine which mechanisms are activated by
KCl in mouse airways, we examined the influence of atropine on
KCl-induced contraction. Atropine dose-dependently inhibited
Mch-induced contraction of mouse airways, and at concentrations
greater than 100 nM it fully blocked the contraction (Figure S5A).
These results confirm the efficacy of atropine in inhibiting
muscarinic receptors in mouse airways. We further found that
atropine (100 nM) reduced KCl (60 mM)-induced contraction to
58%62.5% of the time matched control (Figure S5), implying that
KCl does activate VDCCs in both ASM and cholinergic neurons
to cause airway contractions via a combined effect.
Although L-type VDCCs are the major Ca2+ channel for Ca2+
influx upon depolarization in ASM, and mouse ASM cells exhibit
only L-type Ca2+ currents [17], it is possible that KCl-induced
contraction might involve Rho and Rho kinase via a Ca2+-
independent mechanism [45]. To examine this possibility, we
studied the effect of extracellular Ca2+ on the KCl-induced
increase in [Ca2+]i and contraction. In Ca
2+ containing medium,
KCl (60 mM) induced a marked increase in [Ca2+]i (Figure S6A)
in isolated ASM cells and airway contraction (Figure S6B). Yet in
Ca2+ free medium, the same KCl failed to cause any increase in
[Ca2+]i or a significant contraction (Figure S6B and S6C),
consistent with published results in mouse and rat ASM [46,47].
These results indicate that KCl depolarizes the membrane, leading
to a rise in [Ca2+]i and a resultant contraction in mouse airway.
They also demonstrate that Ca2+ influx is necessary to produce the
KCl-induced contraction, and that a Ca2+-independent mecha-
nism (such as the suggested Rho and Rho kinase pathway)
[45,48,49] is not sufficient (if needed at all) to produce contraction.
To further establish the role of L-type Ca2+ channels in the
KCl-induced rise in [Ca2+]i and contraction, we investigated the
influence of diltiazem on these two effects of KCl. We found that
100 mM diltiazem pretreatment reduced the KCl-induced increase
in DF/F0 from 122%619% to 16.8%610% in isolated ASM cells
(n=9; Figure S6C); it also reversed the KCl-induced contraction
by 93.1%64.8% in airway tissue (n=6; Figure S6D). Therefore,
in mouse ASM, high KCl seems to increase [Ca2+]i and cause
contraction by depolarizing the membrane and activating L-type
VDCCs.
Considering the action of KCl as just described (Figures S5 and
S6), we reasoned that bitter tastants would be able to relax airways
precontracted by KCl if bitter tastant’s inhibition of L-type Ca2+
channels underlies its relaxation of airways pre-contracted by Mch
(Figure 3). Indeed, we found that a 60 mM KCl-induced
contraction in mouse and human airways was fully reversed by
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either chloroquine (1 mM) or denatonium (1 mM) (Figures 4B and
S2C). This reversal is due, at least in part, to a direct inhibition of
VDCCs in ASM because (1) in the presence of 100 nM atropine,
chloroquine can fully block atropine-resistant contraction
(Figure 4B), and (2) when nerve action potentials were blocked
by 1 mM tetrodotoxin, a voltage-dependent Na+ channel blocker,
and arachidonic acid metabolism was inhibited by 1 mM
indomethacin, a nonselective inhibitor of cyclooxygenase, the
bitter tastants still fully relaxed airways precontracted by KCl
(Figure 4B). Similar to their effects on Mch-induced responses
(Figure 2B), chloroquine reversed the KCl-induced increase in
[Ca2+]i and shortening of isolated single ASM cells (Figure 4C;
n=7). Moreover, FPL dose-dependently reversed chloroquine-
induced relaxation in ASM pre-contracted by KCl (60 mM;
Figure 4D), and prevented the reduction of [Ca2+]i by chloroquine
in cells stimulated by KCl (Figure 4E).
Gbc Activation Mediates Bitter Tastant Suppression of
the Rise in [Ca2+]i Evoked by Activation of L-Type VDCCs
To address the signaling basis underlying bitter tastant
inhibition of L-type VDCCs, we studied the impact of perturbing
TAS2R signaling on bitter tastant-induced reversal of the [Ca2+]i
increase in response to KCl in isolated single ASM cells.
Pretreatment with PTX at 1 mg/ml for 6–8 h prevented chloro-
quine-induced reversal of the KCl-induced increase in [Ca2+]i, as
did gallein (20 mM) and anti-bc, a Gbc blocking peptide (1 mM)
(Figure 5). However, U73122 and 2-ABP, at the concentrations
that block the bitter tastant-induced increase in [Ca2+]i in resting
cells (Figure 1), failed to alter chloroquine’s ability to reverse a
KCl-induced increase in [Ca2+]i (Figure 5). These results indicate
that activation of Gbc but not PLCb and IP3R is required for
bitter tastant-induced inhibition of L-type VDCCs.
Discussion
Our results demonstrate that bitter tastant’s reversal of the rise
in [Ca2+]i evoked by bronchoconstrictors is required for its
bronchodilation effect. They also reveal that bitter tastants can
generate different and opposing Ca2+ signals depending upon the
cellular environment. When administered alone to ASM cells at
rest, bitter tastants activate the canonical TAS2R signaling
pathway to modestly raise [Ca2+]i (Figure 5C) without affecting
the contraction. Yet when applied in the presence of the
bronchoconstrictors Mch and KCl, they inhibit L-type VDCCs,
leading to a reversal of both the evoked [Ca2+]i rise and the
contraction (Figure 5C). Remarkably, both types of Ca2+ signals
require Gbc, while only the increase in resting [Ca2+]i depends on
PLCb2 activation and IP3 generation.
Bitter taste receptors (35 in mouse and 25 in human) belong to
seven transmembrane domain G-protein-coupled receptors. Long
thought to only be expressed in the epithelium cells of the taste
buds of the tongue, recent studies have revealed that these
receptors also express in several extraoral tissues including brain,
testis, immune cells, gastrointestinal tract, and respiratory system
[50–57]. In airways, these receptors are found to be expressed in
ciliated epithelial cells and nasal solitary chemosensory cells
[51,52]. Deshpande et al. [6] reported that multiple TAS2Rs can
be detected in cultured human ASM cell lines. In this study, for
the first time, to our knowledge, we found that this class of G-
protein-coupled receptors is expressed in native mouse ASM cells.
Specifically, we determined that TAS2R107, to which both
chloroquine and denatonium are ligands, localizes in the cell
periphery, a location well suited for mediating bronchodilation in
response to these two bitter tastants. We cannot rule out that other
types of TAS2Rs also contribute to the bronchodilation induced
by chloroquine and denatonium, since both of them can activate
multiple mouse and human TAS2Rs [58]. Nevertheless, these
ligands do activate TAS2R signaling transduction, resulting in a
bronchodilation effect, because pharmacological blocking of
multiple downstream components of bitter taste receptors can
prevent chloroquine and denatonium-induced cellular responses
(Figures 1C, 5A, and 5B). It is also worth noting that chloroquine,
denatonium, and all the bitter tastants examined so far are not
endogenous ligands for bitter taste receptors. Hence a major
question remains as to whether bitter taste receptors in ASM cells
have physiological ligands. Interestingly, a recent study revealed
that acyl–homoserine lactones, quorum-sensing molecules for
Gram-negative pathogenic bacteria, can activate bitter tastant
receptors in nasal solitary chemosensory cells to evoke trigeminally
mediated reflex reactions, which may trigger an epithelial
inflammatory response before the bacteria reach population
densities capable of forming destructive biofilms [52,53]. It would
be of great interest and significance to investigate whether these
quorum-sensing molecules can activate bitter taste receptors in
ASM to induce bronchodilation.
This study revealed two major differences in Ca2+ signaling
compared to the study by Deshpande et al. [6]. First, these authors
reported that bitter tastant increased [Ca2+]i to a level comparable
to bronchoconstrictors. In freshly isolated ASM, we found that
bitter tastants only modestly increase [Ca2+]i to a level much lower
than that produced by bronchoconstrictors. Second, Deshpande et
al. [6] reported that bitter tastants generate local Ca2+ events.
However, in freshly isolated ASM, we found that bitter tastants do
not increase local Ca2+ releases such as Ca2+ puffs and Ca2+
sparks. A reason for these two discrepancies may be that
Deshpande et al.’s studies were conducted in cultured ASM cell
lines; compared to freshly isolated ASM, these cells display a
different phenotype by altering the expression of receptors, ion
channels, and contractile proteins [13,14]. The aforementioned
two differences and another difference in which we found that
bitter tastants do not activate large-conductance Ca2+-activated
K+ channels strongly argue that bitter tastant-induced broncho-
dilation is highly unlikely to result from the generation of local
Ca2+ events, which in turn activate large-conductance Ca2+-
activated K+ channel and hyperpolarize the membrane as
proposed [6].
Since bitter tastants relax precontracted airways [6,11,15,16], it
is imperative to use a similar stimulating paradigm in order to
understand the underlying mechanism of this relaxation. By
simultaneously measuring [Ca2+]i and cell shortening, we found
that bitter tastant’s ability to reverse the increase in [Ca2+]i caused
by bronchoconstrictors is the underlying signal producing the
bronchodilation. Three lines of evidence support this conclusion.
First, in the presence of bronchoconstrictors, bitter tastants
lowered [Ca2+]i while at the same time relaxing the precontracted
cells, and this response was reversible. Second, clamping
intracellular [Ca2+]i to levels produced by the bronchoconstrictors
(low mM) prevented bitter tastants from relaxing airways. Third,
enhancing and blocking Ca2+ influx via L-type Ca2+ channels can
oppositely regulate the relaxation mediated by bitter tastants.
These results reinforce the idea that [Ca2+]i is the critical signal
governing ASM contractility.
The opposing Ca2+ signals mediated by Gbc upon activation of
TAS2Rs revealed in this study are unique. It is expected that
gustducin Gbc activates PLCb to generate IP3 and release Ca2+
from endo/sarcoplasmic reticulum to raise [Ca2+]i in ASM cells.
But, unexpectedly, gustducin Gbc also suppresses Ca2+ signaling
mediated by Mch, which largely activates M3R, a Gq family
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receptor. In general, Gbc from the Gi/Go family (to which
TAS2Rs belong) tends to potentiate, rather than, inhibit the Ca2+
responses caused by the Gq family [59,60]. It remains to be
determined whether the inhibition of Ca2+ signaling by TAS2R
activation is Gbc isoform specific. Since Gbc also mediates the
ASM contractions induced by activation of M2R and c-
aminobutyric acid-B receptors [61,62], our present findings
suggested that Gbc reversal of the rise in [Ca2+]i caused by
bronchoconstrictors is isoform specific, and is likely via Gb3c13
dimers, which are released upon activation of TAS2Rs [63].
Further studies using ASM cells with genetic deletions of these
isoforms should facilitate studying this possibility. It is worthy of
mention that virtually all of the studies of bitter taste signaling in
taste buds [7–10] and extraoral tissues [51–53] have focused on
the responses mediated by bitter tastants alone; the opposing Ca2+
signaling mediated by Gbc as revealed in the present study likely
operates in these systems when they are stimulated by a
combination of bitter tastants and other activators.
L-type VDCCs in smooth muscle can be modulated by a variety
of means including phosphorylation and Ca2+ [64–68]. Yet for the
first time, to the best of our knowledge, we show that bc subunits
of G-protein gustducin can inhibit these channels in smooth
muscle, extending the similar findings for cloned Cav1.2 in
heterologous expression cells and Cav1.1 in skeletal muscle fiber
[69,70]. This interpretation is buttressed by the experiments
showing that the contraction mediated by KCl-induced activation
of presynaptic Ca2+ channels can also be fully blocked by bitter
tastants (Figure 4B). What remains unknown is whether Gbc
directly or indirectly inhibits these channels, and the structural
basis for this inhibition. Given that Gbc can directly inhibit K+
channels and N-type Ca2+ channels in several cell types [71–75], it
is likely that Gbc acts on L-type VDCCs in a similar manner.
Gustducin bc subunits inhibit L-type VDCCs to cause
bronchodilation, highlighting the importance of these channels
in mediating bronchoconstriction and their potential as a target for
bronchodilators. Indeed, L-type VDCCs are expressed in ASM
cells and their activation causes these cells to fully contract
(Figures 4, S4, S5, S6) [17,27,76,77]. Also, activation of these
channels is a major mechanism underlying bronchoconstrictor-
induced contraction of different species including airway and
human ([25,27,30,32], but see [24]). Moreover, three classes of
organic L-type VDCC blockers (i.e., dihydropyridines, phenylalk-
ylamines, and benzothiazepines) are effective in relieving airway
spasm in animal models of asthma and in exercise-induced
asthmatic patients [78–81]. A long-standing puzzle regarding L-
type channels in ASM is that clinical trials in the 1980s suggested
that antagonists for this channel were of limited use treating
asthma in the population as a whole [81,82]. A potential reason for
this enigma may be to some extent related to the mode of action of
these blockers. It is known that these classic organic blockers exert
their inactivation of L-type VDCCs in a voltage, stimulation, and
frequency dependent manner [34,36,37]. Interestingly, allergen
sensitized guinea-pig and rabbit ASM cells have a more
hyperpolarized membrane potential than normal cells [83]. This
implies that L-type Ca2+ channel blockers (for example, dihy-
dropyridines) would bind more weakly with these channels, thus
decreasing the efficacy of these agents to inhibit these channels,
should ASM cells from asthma patients have a more negative
membrane potential. Bitter tastants, by their ability to inhibit L-
type Ca2+ channels via activation of gustducin Gbc, perhaps could
circumvent the drawbacks of the currently available L-type Ca2+
channel blockers, and thus be a more effective asthma treatment.
This is likely given that bitter tastants induce a stronger
bronchodilation in both in vitro and in vivo asthmatic mouse
models than do b2 agonists [6,11], the most commonly used
bronchodilators for treating asthma and COPD.
Although bitter tastants are promising candidates to be
developed as a new class of bronchodilators, and the findings in
the present study provide the cellular and molecular rationale for
this line of inquiry, we would caution that chloroquine and
denatonium examined in this study may not be ideal candidates
because of the high concentration (i.e., on the order of 100 mM)
needed to fully relax precontracted ASM. This caveat, however,
should not dampen enthusiasm for this endeavor as there are
many thousands of bitter tastants available from plants and
animals, and numerous bitter small molecules synthesized by
research laboratories and a variety of companies over the years. In
fact, bitter tastants can stimulate bitter taste receptors at
concentrations in the nanomolar range: strychnine activates
human TAS2R46 with an EC50 of 430 nM and aristolochic acid
activates human TAS2R43 with an EC50 of 81 nM [84,85].
Therefore, it is highly likely that bitter tastants with a highly potent
bronchodilating action can be discovered. Searching for these
bitter tastants is of clinical significance because the current
bronchodilators are insufficient for treating severe asthma and
many COPD patients. A critical step in identifying highly potent
bitter tastants is developing reliable and highly effective screening
methodologies. Simultaneous measurements of cell shortening and
the [Ca2+]i signal (i.e., a decrease of elevated [Ca
2+]i), as developed
in the present study, are robust and quantitative and provide a
powerful paradigm for identifying potential bronchodilators from
among the many bitter tastants available.
Figure 4. Bitter tastants block L-type VDCCs. (A) Chloro blocked L-type VDCC currents. Left panel displays patch clamp recordings of L-type
Ca2+ currents in response to a voltage pulse from 270 mV to 0 mV in the control and in the presence of 1 mM chloro, and the right panel the effect
of chloro on the current-voltage (I–V) relationship of the Ca2+ current (n=5). Ba2+ was used as a charge carrier, and the peak current was used to
construct the I–V relationship. Note that the high voltage threshold for activation seen in the I–V relationship, and its sensitivity to FPL and nifedipine
[17] indicate these Ca2+ currents resulted from the opening of L-type VDCCs. (B) Bitter tastants relaxed KCl-induced contraction of mouse airways. The
left panel shows representative force recordings in response to 60 mM KCl followed by 1 mM chloro in the presence of 100 nM atropine and in its
absence. The right panel shows the mean values of the relaxation of KCl-induced contraction by 1 mM chloro in the control (n= 9), in the presence of
100 nM atropine (n=16), or in the presence of 1 mM tetrodotoxin (TTX) and 1 mM indomethacin (Indom) (n=6). Note that the inhibition of chloro in
the presence of 100 nM atropine was calculated relative to the atropine-resistant contraction in response to KCl. Not shown: 1 mM denatonium
relaxed airways precontracted by 60 mM KCl by 97%64% (n= 5 independent experiments). (C) Relationship between [Ca2+]i and cell length in
response to 60 mM KCl and 1 mM chloro. Left panel shows the time course of concomitant changes in [Ca2+]i and cell length and the right the mean
6 SEM (n=15 cells) at the four time points marked on the left. *p,0.05; **p,0.01. (D) FPL 64176 (FPL) dose-dependently inhibited chloro-induced
bronchodilation of KCl precontracted airways. Left panel shows two representative recordings, and the right panel the means 6 SEM (n=5–7
independent experiments). 60 mM KCl and 1 mM chloro were used. Given the non-monotonic nature of the relaxation (left), both the greatest
reduction in force after chloro (i.e., maximum) and the force reduction 5 min after chloro were measured and divided by the peak force- resting force
before application of chloro. (E) FPL inhibited chloro-induced suppression of the rise in [Ca2+]i produced by KCl. Left panel shows original recordings
of Ca2+ responses and the right panel the mean6 SEM (n= 28 without FPL, n=16 with FPL). The values represent as (DF/F0 at the peak after KCl2DF/
F0 at 30 s after chloro)/(DF/F0 at the peak after KCl2DF/F0 at basal)6100.
doi:10.1371/journal.pbio.1001501.g004
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Materials and Methods
Animal Tissue Handling
Experimental protocols for animal research were approved by
the Institutional Animal Care and Use Committees at the
University of Massachusetts Medical School (protocol A-1473 to
RZG).
Isolation of Mouse Airway Smooth Muscle Cells
C57BL/6 mice from 7 to 12 wk of age were anesthetized with
intraperitoneally injected pentobarbitone (50 mg kg21), and the
trachea and mainstem bronchi were quickly removed and placed
in a pre-chilled dissociation solution consisting of (in mM): 135
NaCl, 6 KCl, 5 MgCl2, 0.1 CaCl2, 0.2 EDTA, 10 HEPES, and 10
Glucose (pH 7.3). Tracheas and mainstem bronchi were dissected
free from the surface of the connective tissue. The airway tissue
was incubated in the dissociation medium containing papain 30
unit/ml, 1 mM DTT, and 0.5 mg/ml BSA, at 35uC for 30 min,
and then transferred to a dissociation medium containing 3 unit/
ml collagenase F and 0.5 mg/ml BSA, and incubated at 35uC for
another 15 min to produce isolated ASM cells. Finally, the tissue
was agitated with a fire polished wide-bore glass pipette to release
the cells.
Mouse Airway Smooth Muscle Contraction Bioassay
C57BL/6 mice at 7–12 wk of age were sacrificed and the entire
respiratory trees were rapidly removed and immersed in Krebs
physiologic solution containing (in mM) 118.07 NaCl, 4.69 KCl,
2.52 CaCl2,1.16 MgSO4, 1.01 NaH2PO4, 25 NaHCO3, and 11.10
glucose. Trachea and mainstem bronchi were isolated and cut into
rings (4 mm in length). The rings were mounted on a wire
myograph chamber (Danish Myo Technology), and a PowerLab
recording device (AD Instruments) was used to record isometric
tension. The ring preparations with zero tension were immersed in
5 ml of Krebs physiologic solution, bubbled with 95% O2 and 5%
CO2 at 37uC. After 10 min equilibration, three stretches (each
2.5 mN) at 5 min intervals were applied to the rings. After these
stretches the basal tones of the rings were usually settled at
approximately 2 mN. To test the contractile response, each ring
was stimulated twice with KCl (60 mM), separated by 20 min,
before proceeding to other treatments. The order and treatment
time of agonists and antagonists are indicated in the figure
captions. In the experiments in Figures 4B, S4B, and S4D, 1 mM
tetrotodoxin was added to prevent action potentials of neurons
and 1 mM indomethacin to inhibit cyclooxygenase. The force in
response to 60 mM KCl in the presence of tetrodotoxin and
indomethacin was 95%67% (n=6) of that in their absence.
Airway Smooth Muscle Permeabilization
Mouse bronchi rings (4 mm in length) free of connective tissues
were incubated for 5 min in HEPES-Tyrode (H-T) buffer which
contained 137.0 mM NaCl, 2.7 mM KCl, 1.0 mM MgCl2,
1.8 mM CaCl2, 10 mM HEPES, 5.6 mM glucose (pH 7.4). The
rings were then transferred to and incubated in Ca2+-free H-T
buffer for 5 min followed by another 5 min in buffer A (30 mM
TES, 0.5 mM DTT, 50 mM KCl, 5 mM K2EGTA, 150 mM
Figure 5. Bitter tastants inhibit L-type VDCCs via a Gbc
dependent process. (A) Representative recordings of changes in
[Ca2+] in response to 60 mM KCl followed by chloro (I mM) with and
without pretreatment with PTX (1 mg/ml), gallein (1 mM), anti-bc
blocking peptide (1 mM), U73122 (3 mM), and 2-APB (50 mM). The
application protocols for these compounds were the same as in the
experiments in Figure 1C. All data were scaled to have a maximum of
100 and aligned at the time point when KCl was administrated. (B)
Effects of compounds listed in A on chloro-induced suppression of KCl-
induced increase in [Ca2+]i. The values were calculated the same as in
Figure 4E. Compared to the control (i.e., chloro alone after KCl, black
filled bar), p,0.0001 for PTX, gallein, and anti-bc; and p.0.05 for
U73122 and 2-APB. Data are shown as mean6 SEM (n= 12–38 cells). (C)
A model for TAS2R signaling and bitter tastant-induced bronchodila-
tion. We propose that bitter tastants activate the canonical TAS2R
signaling cascade; this modestly increases [Ca2+]i in resting cells but
exerts no significant effect on resting tone. On the other hand,
activation of TAS2Rs activates gustducin and release Gbc, which turns
off L-type VDCCs that are pre-activated by bronchoconstrictors, leading
to bronchodilation.
doi:10.1371/journal.pbio.1001501.g005
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sucrose [pH 7.4]). To skin ASM, the rings were incubated for
45 min with a-toxin (16,000 units/ml) in buffer A at room
temperature. After the permeabilization, the rings were treated
with 10 mM ionomycin for 10 min to deplete intracellular Ca2+
stores.
Skinned airway rings were mounted on the wire myograph
chamber and washed two times with pCa 9 solution (20 mM TES,
4 mM K2EGTA, 5.83 mM MgCl2, 7.56 mM potassium propio-
nate, 3.9 mM Na2ATP, 0.5 mM dithioerythritol, 16.2 mM
phosphocreatine, 15 units/ml creatine kinase [pH 6.9]). The
viability of the skinned muscle rings was examined by stimulation
with pCa 4.5 solution (20 mM TES, 4 mM CaEGTA, 5.66 mM
MgCl2, 7.53 mM potassium propionate, 3.9 mM Na2ATP,
0.5 mM dithioerythritol, 16.2 mM phosphocreatine, 15 units/ml
creatine kinase [pH 6.9]) followed by the pCa 9.0 solution. The
muscles that could generate sustained contraction in response to
the pCa 4.5 solution and fully relax when exposed to the pCa 9.0
solution were used for subsequent experiments. To test the effect of
bitter tastants, the viable muscle rings were induced to contract by
exposure to pCa 5.5 solution followed by the administration of
bitter tastants at the concentrations indicated in Figure 3.
Measurement of Global [Ca2+]i and Ca
2+ Sparks
Fluorescence images using fluo-3 as a calcium indicator were
obtained using a custom-built wide-field digital imaging system.
The camera was interfaced to a custom made inverted
microscope, and the cells were imaged using either a 206Nikon
1.3 NA for global [Ca2+] measurement or a 606Nikon 1.4 NA oil
for Ca2+ spark measurement. The 488 nm line of an Argon Ion
laser provided fluorescence excitation, with a shutter to control
exposure duration, and emission of the Ca2+ indicator was
monitored at wavelengths .500 nm. The images were acquired at
the speed of either 1 Hz for global [Ca2+] measurement or 50 Hz
for Ca2+ spark measurement. Subsequent image processing and
analysis was performed off line using a custom-designed software
package, running on a Linux/PC workstation. [Ca2+]i was
represented as DF/F06100 with F calculated by integrating fluo-
3 over entire cells for global [Ca2+] after background correction
with areas free of cells, or just the value at the brightest pixel (i.e.,
epicenter pixel) for Ca2+ sparks.
Patch-Clamp Recording
Membrane currents were recorded with an EPC10 HEKA
amplifier under perforated whole-cell patch recording configura-
tion. The extracellular solution contained (in mM): NaCl 126,
tetraethylammonium Cl 10, BaCl2 2.2, MgCl2 1, Hepes 10, and
glucose 5.6 (pH adjusted to 7.4 with NaOH). The pipette solution
contained (in mM): CsCl 139, MgCl2 1, Hepes 10, MgATP 3,
Na2ATP 0.5 (pH adjusted to 7.3 with KOH); amphotericin B was
freshly made and added to the pipette solution at a final
concentration of 200 mg/ml. Whole-cell Ba2+ currents were
evoked by step depolarization with 300 ms duration every 10 s
from a holding potential of 270 mV at a 10 mV increment
(Figure 4A) or with protocol as described in the caption of figure
caption (Figure S4C). Currents were leak corrected using a P/4
protocol.
Measurement of Cell Shortening
Myocytes were placed into a recording chamber superfused
with the bath solution for patch clamp experiments at room
temperature. Cells loaded with Fluo-3 were imaged using a
custom-built wide-field digital imaging system and their lengths
were determined using custom software to manually trace down
the center of the cell [17].
Reverse Transcription-PCR to Detect mRNA
The connective tissues in trachea and mainstem bronchi were
carefully removed and the ASM were then quickly frozen in dry
ice. The total RNA of the ASM was isolated with the TRIzol
(Invitrogen) method following the manufacturer’s guidelines; and
cDNA was synthesized using extracted RNA with an Omniscript
Reverse Transcription kit (Qiagen). The specific primers, synthe-
sized by Invitrogen, are listed in Table S1. b-actin was used as a
positive control and the absence of DNA as a negative control, and
the PCR reactions were carried out in a PCR mastercycler.
Immunocytochemistry
Mouse ASM cells, isolated as described above and plated onto
poly-L-lysine coated coverslips were fixed and permeabilized
(0.1 M ethanolamine in PBS plus 0.1% triton X-100 [pH 8]) and
then immunolabeled as described previously [86]. Anti-
TAS2R107, an affinity purified rabbit polyclonal antibody raised
against a peptide mapping within an extracellular domain of
mouse TAS2R107, was purchased from Santa Cruz Biotechnol-
ogy (sc-139175), and purified IgG was used as control.
3D fluorescence imaging was performed on an inverted wide
field microscope (Nikon Diaphot 200) with excitation by a 100 W
mercury lamp. Images were obtained through a 606objective and
digitally recorded on a cooled, back-thinned CDD camera
(Photometrics), with an effective pixel size at the specimen of
83 nm in x-y and a z spacing of 100 nm. This resulted in a 3D
stack of approximately 100 image planes for each cell.
The fluorescence images were deconvolved with a constrained,
iterative approach [87] originally designed for UNIX systems. The
algorithm was rewritten using FFTW, a free, fast Fourier
transform library and implemented as a multiuser client/server
system on computers running the Fedora operating system (Red
Hat), either stand-alone or configured in a Beowulf cluster. Each
image was dark current and background subtracted, flat-field
corrected, and then deconvolved. After deconvolution images
were thresholded to eliminate non-specific binding. Voxels that fell
below a threshold were considered to be non-specific bindings and
were set to zero; all other voxels remained unchanged. This
threshold was derived from analysis of control images containing
purified IgG. The intensity which eliminated 99% of the voxels in
the control images became the threshold intensity.
Reagents and Their Application
All chemicals, except fluo-3 (Invitrogen Co), gallein (Tocris
Bioscience), anti-bc blocking peptide (AnaSpec), anti-TAS2R107
(Santa Cruz Biotechnology), and purified IgG (Jackson Immu-
noResearch Laboratories) were purchased from Sigma-Aldrich
Co. For single cell studies, agonists and antagonists were applied
locally to cells via a picospritzer at a constant pressure, so that the
duration of its action and concentration could be controlled easily.
Statistics
Unless stated otherwise, data are reported as mean 6 standard
error of the mean (SEM) and n represents the number of cells or
trachea and mainstem bronchi. Statistical analysis of differences
was made with Student’s paired or unpaired t-test and the
significance level was set at p,0.05.
Supporting Information
Figure S1 Bitter tastant chloroquine dose-dependently
increased [Ca2+]i in resting single cells (A) without a
significant effect on the contractility (B) of relaxed
mouse airways. Results are mean 6 SEM, (n=5–30 cells in
bc-Gustducin Inhibits L-Type Ca2+ Channel
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(A) and 7 airway rings in (B)). Dose response curves in (A) were
generated on the basis of the responses to single dose administra-
tion, while that in (B) was based on accumulative administration.
Note that Mch produced much larger responses.
(TIFF)
Figure S2 Characteristics of [Ca2+]i and contractile
responses to bitter tastants and diltiazem in human
ASM. (A) Bitter tastants reversed the [Ca2+]i rise and cell shortening
induced byMch. Measurements were taken at the steady state levels
in response to Mch and chloroquine. The cell length before
stimulation was considered as 100%. *p,0.05 paired Student’s t-
test; ***p,0.001; n=6–12. (B) L-type VDCC blocker diltiazem
dose-dependently reversed 10 mM Mch-induced contraction (n=5
independent experiments). % relaxation= tension decrease due to
diltiazem divided by tension increase due to Mch, times 100. The
tension decrease at each concentration of diltiazem is measured
once the tension stabilizes. The tension decrease at each increased
concentration is always measured relative to the peak tension (i.e., it
is total decrease, not the incremental decrease due to the additional
diltiazem which was added). (C) Chloroquine (1 mM) and diltiazem
(100 mM) relaxed human intrapulmonary bronchi precontracted by
60 mM KCl (n=3–5 independent experiments). % relaxation=
tension decrease due to chloroquine divided by tension increase due
to Mch, times 100. Bar charts are mean 6 SEM. Human lung
tissues were obtained (with informed consent) from patients
undergoing surgery (lobectomy) for lung cancer at the Department
of Surgery and the Department of Pathology at the University of
Massachusetts Memorial Medical Center (Worcester). The tumors
were identified as non–small cell carcinoma (adenocarcinoma or
squamous cell carcinoma). Intrapulmonary airways were dissected
out and cleaned free of the connective tissues. These airways were
either cut into the rings (4 mM in length) for force measurements
the same as for mouse airway tissues, or digested with the same
enzymes, dissociation medium, and isolation procedure as for single
mouse ASM cells. The experimental protocols on human tissues
were approved by the Committee for Protection of Human Subjects
in Research at the University of Massachusetts Medical School
(protocol 13590 to RZG).
(TIFF)
Figure S3 Ca2+ influx plays a major role in producing
and maintaining Mch-induced increases in [Ca2+]i and
contraction in mouse ASM. (A) In Ca2+ free medium, the
tension generated by Mch was less than 20% of that in the
presence of extracellular Ca2+. ***p,0.001, Student’s paired t-test,
n=9 airway rings for the group with Ca2+, and n=10 airway rings
for the group without Ca2+. (B) Mch increased [Ca2+]i much less in
Ca2+ free medium than in the presence of extracellular Ca2+. In
the absence of extracellular Ca2+, Mch (10 mM) produced different
patterns of changes in [Ca2+]i, so the area under each curve was
calculated for 1 min of Mch stimulation and compared between
the two conditions (right panel). ***p,0.001 with extracellular
Ca2+ (n=9 cells) versus without the Ca2+ (n=12 cells); Student’s
unpaired t-test. (C) Ca2+ stores remained functional in the absence
of extracellular Ca2+. The cells were placed in the absence of
extracellular Ca2+ for ,15 min, and then stimulated with two
10 mM Mch pulses 15 min apart. The chart on the right indicates
that two Mch administrations produced comparable Ca2+
responses, i.e., Ca2+ stores are intact under experimental
conditions in the present study. NS, p.0.05 for the response in
the first pulse of Mch versus that in the second pulse, Student’s
paired t-test, n=10. DF/F0 for (B) and (C) are the average over the
entire cell.
(TIFF)
Figure S4 Role of L-type Ca2+ channel activation in
Mch-induced contraction in mouse airway. (A) Left panel:
L-type VDCC blocker diltiazem dose-dependently reversed Mch-
induced contraction (using tension as a proxy measure). Right
panel: results for n=6 airway rings. % relaxation was calculated
the same as in Figure S2B. (B) Diltiazem inhibited Mch- and KCl-
induced contraction in a dose-dependent manner. (i) Once
equilibrated, airway rings generated stable responses to 60 mM
KCl (i.e., K0, K1, and K2), and to 1 mM Mch (i.e., M0 and M1)
over a time span longer than 1 hr. (ii, iii, iv) show representative
responses to KCl and Mch in the presence of diltiazem at 1 mM,
10 mM, and 100 mM, respectively. Two pulses of KCl (K1 and
K2) were administrated before Mch (M1) to facilitate diltiazem
inactivation of L-type Ca2+ channels. (v) Dose-response curve for
diltiazem-mediated inhibition of contraction by KCl. Data are
mean6 SEM (n=5); % inhibition= (force by K02 force by K2)/
(force by K0)6100. (vi) Dose-response curve for diltiazem-
mediated inhibition of contraction by Mch. Data are mean 6
SEM (n=5); % inhibition= (force by M0 – force by M1)/(force by
M0)6100. Forces are measured at their peak, excluding the noise
spikes due to the washing out of KCl or Mch. (C) Diltiazem
inhibited L-type VDCC currents in a dose-dependent manner.
Diltiazem was added to the bath solution cumulatively. Once at
equilibrium at each level of diltiazem, cells were stimulated with a
train of ten voltage pulses from 270 mV to 0 mV (inset) at 10 s
intervals. Left panel displays patch clamp recordings of L-type
Ca2+ currents in the control and in the presence of diltiazem at the
given concentration (each in response to the tenth voltage pulse),
and the right panel depicts the effect of diltiazem on the peak
current at different concentrations. Ba2+ was used as the charge
carrier. Data are mean 6 SEM (n=6); % inhibition= (peak
current of the control 2 peak current at given diltiazem
concentration)/peak current of the control 6100 (measured in
the tenth voltage pulse). (D) Effect of nisoldipine on Mch-induced
contraction. In light of the voltage-dependence of the inhibition of
nisoldipine on L-type VDCCs, airway rings were modestly
depolarized with 20 mM KCl (red bars) before Mch stimulation.
Left panel displays a representative contractile response to 60 mM
KCl and 1 mM Mch before and after 1 mM nisoldipine. Right
panel shows the mean values (mean 6 SEM) of inhibition by
1 mM nisoldipine of contraction evoked by KCl and Mch,
respectively. % inhibition= (maximal force at the control 2
maximal for with nisoldipine)/maximal force at the control6100.
(TIFF)
Figure S5 KCl activates VDCCs in cholinergic nerves
and ASM. (A) Atropine dose-dependently inhibited Mch-induced
mouse airway contraction. The left panels display representative
contractile responses to 3 mM Mch in the absence or the presence
of atropine as marked near the traces, and the right panel shows
the mean values (mean 6 SEM; n=4–8) of inhibition by atropine
of contraction evoked by 3 mM Mch. % inhibition= (maximal
force from the control 2 maximal force with atropine)/maximal
force from the control6100. (B) Atropine inhibited KCl-induced
mouse airway contraction. The left panel shows a representative
tension recording in response to 60 mM KCl before and after
100 nM atropine, as marked beneath. The right panel shows the
summarized results as the ratio of the force generated by the
second KCl pulse over first KCl pulse (mean 6 SEM; n=6 for the
time matched controls, n=28 for atropine).
(TIFF)
Figure S6 KCl activates L-type VDCCs to increase
[Ca2+]i and cause contraction in mouse ASM. (A) KCl
failed to generate any global [Ca2+]i increase in the absence of
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extracellular Ca2+ in isolated single ASM cells. (i) A representative
[Ca2+]i response to 60 mM KCl in the presence of extracellular
Ca2+. (ii, iii, iv) three examples showing that the same
concentration of KCl did not increase Ca2+ in the zero Ca2+
medium. This failure was not due to the depletion of intracellular
Ca2+ stores because 10 mM Mch still induced Ca2+ release either
as a single peak or as oscillations. Eight cells gave rise to similar
responses. DF/F0 is the average over the entire cell. (B) KCl
(60 mM) caused virtually no increase in tension in the absence of
extracellular Ca2+. The airways were placed in the Ca2+ free
solution for 15 min before the measurement commenced. Left
panel shows a pair of representative recordings and right panel the
average results. **p,0.01, Student’s paired t-test, n=6 indepen-
dent experiments. (C) KCl (60 mM)-induced increase in [Ca2+]i
was markedly inhibited by prior application of L-type VDCC
blocker diltiazem (100 mM). **p,0.01, Student’s paired t-test,
n=9 for each conditions. (D) Diltiazem (100 mM) relaxed 60 mM
KCl-induced contraction of mouse airways. Data are mean 6
SEM (n=6 independent experiments), and % relaxation definition
and analysis are the same as in Figure S2C.
(TIFF)
Table S1 Primers for Reverse Transcription-PCR.
(TIFF)
Movie S1 This clip shows 1 mM chloro reversed the 100 mM
Mch-induced increase in [Ca2+]i and cell shortening; the first 120
images of this clip were analyzed and plotted in Figure 2A. The
images are displayed as fluorescence intensity (rather than DF/F0)
because the cell changes its shape dramatically in response to
stimuli (and changing thickness makes DF/F0 measures mislead-
ing).
(MOV)
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